At a glance
ClinicalIndex Comparison RecordN/ACompleted· 72 enrolled
Drug / intervention
Aline HAdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label, Prospective Study of Implanted Cross-linked HA Device, Aline HA, for Soft Tissue Augmentation, to Treat Only One Anatomic Feature in up to 100 Subjects for 6 Months
In Brief
A clinical study evaluating Aline HA for Disorder of Soft Tissue. Completed, enrolled 72 participants across 2 sites.
Detailed Summary
The protocol hypothesis is that treatment with Aline HA™ will be safe through 6 months as determined by clinical assessment of treatment sites and routine tracking of adverse events.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisorder of Soft Tissue
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedOct 2012
Primary CompletionNov 2013
Study CompletionDec 2013
TodayJul 2026
First PostedOct 16, 2012
Enrollment StartOct 1, 2012
Primary CompletionNov 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.7 years ago
Interventions
Aline HAdevice
Implantable dermal filler